TY - JOUR
T1 - How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
AU - Chang, Ying Jun
AU - Luznik, Leo
AU - Fuchs, Ephraim J.
AU - Huang, Xiao Jun
N1 - Funding Information:
This work was supported (in part) by the National High Technology Research and Development Program of China (Program 863) (Grant No. 2013AA020401), the Milstein Medical Asian American Partnership Foundation, The Key Program of the National Natural Science Foundation of China (Grant No. 81230013), the Scientific Research Foundation for Capital Medicine Development (Grant No. 2011-4022-08), and the National Cancer Institute of the National Institutes of Health (CA 015396), USA. We would also like to thank San Francisco Edit (www.sefedit.net) for assistance in editing this manuscript.
PY - 2016
Y1 - 2016
N2 - In haploidentical stem cell transplantations (haplo-SCT), nearly all patients have more than one donor. A key issue in the haplo-SCT setting is the search for the best donor, because donor selection can significantly impact the incidences of acute and chronic graft-versus-host disease, transplant-related mortality, and relapse, in addition to overall survival. In this review, we focused on factors associated with transplant outcomes following unmanipulated haplo-SCT with anti-thymocyte globulin (ATG) or after T-cell-replete haplo-SCT with post-transplantation cyclophosphamide (PT/Cy). We summarized the effects of the primary factors, including donor-specific antibodies against human leukocyte antigens (HLA); donor age and gender; killer immunoglobulin-like receptor-ligand mismatches; and non-inherited maternal antigen mismatches. We also offered some expert recommendations and proposed an algorithm for selecting donors for unmanipulated haplo-SCT with ATG and for T-cell-replete haplo-SCT with PT/Cy.
AB - In haploidentical stem cell transplantations (haplo-SCT), nearly all patients have more than one donor. A key issue in the haplo-SCT setting is the search for the best donor, because donor selection can significantly impact the incidences of acute and chronic graft-versus-host disease, transplant-related mortality, and relapse, in addition to overall survival. In this review, we focused on factors associated with transplant outcomes following unmanipulated haplo-SCT with anti-thymocyte globulin (ATG) or after T-cell-replete haplo-SCT with post-transplantation cyclophosphamide (PT/Cy). We summarized the effects of the primary factors, including donor-specific antibodies against human leukocyte antigens (HLA); donor age and gender; killer immunoglobulin-like receptor-ligand mismatches; and non-inherited maternal antigen mismatches. We also offered some expert recommendations and proposed an algorithm for selecting donors for unmanipulated haplo-SCT with ATG and for T-cell-replete haplo-SCT with PT/Cy.
KW - Age
KW - Donor
KW - Donor-specific anti-human leukocyte antigen antibody
KW - Natural killer alloreactivity
KW - Non-inherited maternal antigen mismatch
KW - Unmanipulated haploidentical stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=85007530019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007530019&partnerID=8YFLogxK
U2 - 10.1186/s13045-016-0265-2
DO - 10.1186/s13045-016-0265-2
M3 - Review article
C2 - 27071449
AN - SCOPUS:85007530019
SN - 1756-8722
VL - 9
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 35
ER -